PLX vs. BRK-B
PLX (Protalix BioTherapeutics, Inc.) and BRK-B (Berkshire Hathaway Inc.) are both stocks. PLX operates in Biotechnology (Healthcare), while BRK-B operates in Insurance - Diversified (Financial Services). Over the past 10 years, PLX returned -13.01%/yr vs 12.91%/yr for BRK-B. At a 0.11 correlation, their price movements are largely independent.
Performance
PLX vs. BRK-B - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PLX achieves a 8.89% return, which is significantly higher than BRK-B's -5.43% return. Over the past 10 years, PLX has underperformed BRK-B with an annualized return of -13.01%, while BRK-B has yielded a comparatively higher 12.91% annualized return.
PLX
- 1D
- -1.51%
- 1M
- -7.98%
- YTD
- 8.89%
- 6M
- 13.95%
- 1Y
- 22.50%
- 3Y*
- -3.92%
- 5Y*
- -1.74%
- 10Y*
- -13.01%
BRK-B
- 1D
- 0.82%
- 1M
- 1.46%
- YTD
- -5.43%
- 6M
- -5.61%
- 1Y
- -4.51%
- 3Y*
- 13.00%
- 5Y*
- 10.20%
- 10Y*
- 12.91%
PLX vs. BRK-B - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
PLX Protalix BioTherapeutics, Inc. | 8.89% | -4.26% | 5.62% | 29.93% | 64.72% | -77.09% | 10.67% | 5.47% | -52.96% | 48.58% |
BRK-B Berkshire Hathaway Inc. | -5.43% | 10.89% | 27.09% | 15.46% | 3.31% | 28.95% | 2.37% | 10.93% | 3.01% | 21.62% |
Correlation
The correlation between PLX and BRK-B is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.06 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.12 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.15 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.12 |
Correlation (All Time) Calculated using the full available price history since May 18, 1998 | 0.11 |
Fundamentals
PLX:
$162.78M
BRK-B:
$1.03T
PLX:
$0.19
BRK-B:
$33.62
PLX:
10.34
BRK-B:
14.14
PLX:
2.08
BRK-B:
2.73
PLX:
1.72
BRK-B:
1.41
PLX:
$76.38M
BRK-B:
$375.39B
PLX:
$53.44M
BRK-B:
$94.36B
PLX:
$20.91M
BRK-B:
$71.92B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PLX vs. BRK-B — Risk / Return Rank
PLX
BRK-B
PLX vs. BRK-B - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Protalix BioTherapeutics, Inc. (PLX) and Berkshire Hathaway Inc. (BRK-B). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| PLX | BRK-B | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.34 | -0.32 | +0.66 |
Sortino ratioReturn per unit of downside risk | 0.92 | -0.34 | +1.26 |
Omega ratioGain probability vs. loss probability | 1.12 | 0.96 | +0.16 |
Calmar ratioReturn relative to maximum drawdown | 0.57 | -0.48 | +1.05 |
Martin ratioReturn relative to average drawdown | 1.07 | -1.02 | +2.09 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| PLX | BRK-B | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.34 | -0.32 | +0.66 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.03 | 0.60 | -0.62 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.16 | 0.67 | -0.83 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.07 | 0.48 | -0.54 |
Drawdowns
PLX vs. BRK-B - Drawdown Comparison
The maximum PLX drawdown since its inception was -99.91%, which is greater than BRK-B's maximum drawdown of -53.86%. Use the drawdown chart below to compare losses from any high point for PLX and BRK-B.
Loading charts...
Drawdown Indicators
| PLX | BRK-B | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.91% | -53.86% | -46.05% |
Max Drawdown (1Y)Largest decline over 1 year | -39.68% | -9.42% | -30.26% |
Max Drawdown (3Y)Largest decline over 3 years | -62.96% | -14.95% | -48.01% |
Max Drawdown (5Y)Largest decline over 5 years | -73.21% | -26.58% | -46.63% |
Max Drawdown (10Y)Largest decline over 10 years | -94.37% | -29.57% | -64.80% |
Current DrawdownCurrent decline from peak | -99.78% | -11.94% | -87.84% |
Average DrawdownAverage peak-to-trough decline | -93.66% | -11.07% | -82.59% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 21.01% | 4.57% | +16.44% |
Volatility
PLX vs. BRK-B - Volatility Comparison
Protalix BioTherapeutics, Inc. (PLX) has a higher volatility of 13.87% compared to Berkshire Hathaway Inc. (BRK-B) at 3.75%. This indicates that PLX's price experiences larger fluctuations and is considered to be riskier than BRK-B based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PLX | BRK-B | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.87% | 3.75% | +10.12% |
Volatility (6M)Calculated over the trailing 6-month period | 44.36% | 10.68% | +33.68% |
Volatility (1Y)Calculated over the trailing 1-year period | 66.69% | 14.33% | +52.36% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 67.72% | 17.11% | +50.61% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 79.33% | 19.43% | +59.90% |
Dividends
PLX vs. BRK-B - Dividend Comparison
Neither PLX nor BRK-B has paid dividends to shareholders.
Financials
PLX vs. BRK-B - Financials Comparison
This section allows you to compare key financial metrics between Protalix BioTherapeutics, Inc. and Berkshire Hathaway Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
PLX vs. BRK-B - Profitability Comparison
PLX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Protalix BioTherapeutics, Inc. reported a gross profit of 29.62M and revenue of 33.75M. Therefore, the gross margin over that period was 87.8%.
BRK-B - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Berkshire Hathaway Inc. reported a gross profit of 26.98B and revenue of 93.68B. Therefore, the gross margin over that period was 28.8%.
PLX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Protalix BioTherapeutics, Inc. reported an operating income of 21.15M and revenue of 33.75M, resulting in an operating margin of 62.7%.
BRK-B - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Berkshire Hathaway Inc. reported an operating income of 15.05B and revenue of 93.68B, resulting in an operating margin of 16.1%.
PLX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Protalix BioTherapeutics, Inc. reported a net income of 18.32M and revenue of 33.75M, resulting in a net margin of 54.3%.
BRK-B - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Berkshire Hathaway Inc. reported a net income of 10.18B and revenue of 93.68B, resulting in a net margin of 10.9%.
Frequently Asked Questions
PLX and BRK-B have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
PLX has higher volatility (13.87%) compared to BRK-B (3.75%). In terms of maximum drawdown, PLX dropped -99.91% vs BRK-B's -53.86%.
PLX currently has the higher Sharpe Ratio (0.34 vs -0.32), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PLX and BRK-B
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer